G6PD diaxBox: Digital image-based quantification of G6PD deficiency

Talanta. 2021 Oct 1:233:122538. doi: 10.1016/j.talanta.2021.122538. Epub 2021 May 26.

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy in humans. More than 400 million people worldwide are affected by this genetic condition. Testing for G6PD deficiency before drug administration is essential for patient safety. Rapidly ascertaining the G6PD status of a person is desirable for proper treatment. The device described in this study, the G6PD diaxBOX, was developed to quantify G6PD deficiency using paper-based analytical devices (PADs) and a colorimetric assay. The G6PD diaxBOX is a straightforward, affordable, portable, and instrument-free analytical system. The major components of the G6PD diaxBox are a banknote-checking UV fluorescent lamp and camera that are easy to access and analysis software. When NADPH is generated, it absorbs at UV 340 nm and emits colored light that is detected with the camera. The determined Pearson's coefficient shows that the color intensity measured from the G6PD diaxBOX correlated with G6PD activity level. Also, a Bland-Altman analysis indicated that more than 95% of the measurement error was in the upper and lower boundaries (±2 SD) and the error from the severe and moderate deficiency group was less than ± 1 SD. Therefore, the error from G6PD diaxBOX was within the limit boundary and the overall accuracy was more than 80%. The G6PD diaxBOX facilitates the effective and efficient quantification of G6PD deficiency and as such represents a clinically well-suited, rapid point-of-care test.

Keywords: Glucose-6-phosphate dehydrogenase deficiency; NADPH; Paper-based analytical device; Point-of-care (POC) test; UV 340 nm.

MeSH terms

  • Colorimetry
  • Glucosephosphate Dehydrogenase Deficiency*
  • Glucosephosphate Dehydrogenase*
  • Humans
  • Point-of-Care Testing
  • Software

Substances

  • Glucosephosphate Dehydrogenase